Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Speedel Could Market Blood Clot Candidate On Its Own

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

After Abbott announces it will not exercise a license-back option, the Swiss firm is considering several options.

You may also be interested in...



Tekturna Launch Anticipated “Very Quickly” Following Approval

Novartis has recruited an additional 1,000 sales reps in preparation for the launch of the antihypertensive, according to partner Speedel.

Tekturna Launch Anticipated “Very Quickly” Following Approval

Novartis has recruited an additional 1,000 sales reps in preparation for the launch of the antihypertensive, according to partner Speedel.

Novartis/Speedel Anti-Hypertensive Rasilez Could Reach Market By Year-End

NDA for the oral renin inhibitor, submitted in the first quarter, seeks monotherapy and combination treatment claims.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

See All
UsernamePublicRestriction

Register

PS064684

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By